LeMaitre Vascular, Inc. filings document a Nasdaq-listed medical device company focused on vascular devices, implants, and services for peripheral vascular disease. Recent Form 8-K reports furnish quarterly operating and financial results, dividend-related updates, and related press release exhibits.
Proxy and governance filings cover board structure, director elections, executive compensation, advisory say-on-pay matters, and shareholder voting results. The filings also identify the company’s common stock, par value, Nasdaq Global Market listing under LMAT, and related public-company disclosure controls.
LeMaitre Vascular, Inc. (LMAT) reported third-quarter 2026 net sales of $67.970 million, up from $61.046 million a year earlier, while net income was $15.024 million versus $17.362 million. Diluted earnings per share were $0.65, compared with $0.75. For the first nine months, net sales were $204.903 million versus $185.149 million, and net income was $47.753 million versus $42.152 million; diluted earnings per share were $2.07 versus $1.84.
Operating cash flow for the nine months was $53.048 million, down from $58.094 million. At September 30, 2026, LMAT had $27.493 million of cash and cash equivalents and $362.228 million of short-term marketable securities. The board authorized up to $100.0 million of share repurchases through February 18, 2027; no repurchases had been made under the program. It approved a $0.25 quarterly dividend payable December 3, 2026, to shareholders of record November 19. Convertible senior notes had $172.5 million of principal outstanding and mature February 1, 2030.
LeMaitre Vascular (LMAT) reported preliminary, unaudited Q3 2026 net sales of $67.970 million, versus $61.046 million a year earlier. Organic sales growth was 12%, comprising 7% price and 5% unit growth. Net income was $15.024 million versus $17.362 million, and diluted EPS was $0.65 versus $0.75. Gross margin was 71.7%, up 90 basis points from adjusted Q3 2025; operating expenses rose 18% against the adjusted prior-year comparison. Adjusted EBITDA was $20.498 million, up 7%.
In October, LeMaitre acquired certain vascular assets from B. Braun for $19.2 million. The products recorded $9.4 million in 2025 sales, all outside North America. Sales will transition to LeMaitre’s channel over 18–24 months as customer contracts conclude or transfer; during the transition, LeMaitre will receive a portion of profits on B. Braun-originated sales. Full-year 2026 guidance is $274.8–$276.8 million in sales and $2.77–$2.82 EPS. The board approved a $0.25-per-share quarterly dividend, payable December 3, 2026, to holders of record November 19, 2026.
LeMaitre Vascular, Inc. says David B. Roberts notified the company on October 9, 2026, of his intent to retire as an employee, including as president, effective December 31, 2026. Roberts was reelected as a director at the 2026 Annual Meeting of Stockholders for a term ending in 2029 and intends to continue serving on the Board after retiring as president. The company thanked him for 29 years of executive service.
LEMAITRE VASCULAR INC (LMAT) reported that President and Director David B. Roberts received nine small grants of Dividend Equivalent Rights on September 3, 2026. These rights accrued on previously granted restricted stock unit and performance share unit awards and vest proportionately with those awards. Each dividend equivalent right is the economic equivalent of one share of common stock, carries no cash exercise price, and no Rule 10b5-1 trading plan is reported.
LEMAITRE VASCULAR INC (symbol: LMAT) is the issuer of record for a Form 4 filing submitted to the SEC. Pellegrino Joseph P JR reported acquisition or exercise transactions in this Form 4 filing.
LEMAITRE VASCULAR INC (LMAT) reported that director Joseph P. Pellegrino, Jr. received several small awards of dividend equivalent rights on September 3, 2026, each tied to previously granted restricted stock unit and performance share unit awards. Each right is the economic equivalent of one share of common stock and vests proportionately with the underlying award.
LeMaitre Vascular Inc (LMAT) director Lawrence J. Jasinski reported the acquisition of several small blocks of Dividend Equivalent Rights on September 3, 2026. These rights accrued on previously granted restricted stock unit and performance share unit awards and are the economic equivalent of LeMaitre common shares, vesting proportionately with the underlying awards. No Rule 10b5-1 trading plan is reported.
LEMAITRE VASCULAR INC (symbol: LMAT) is the issuer of record for a Form 4 filing submitted to the SEC. SHADAN MARTHA reported acquisition or exercise transactions in this Form 4 filing.
LEMAITRE VASCULAR INC (LMAT) director Martha Shadan reported several small awards of Dividend Equivalent Rights on September 3, 2026. These derivative rights accrued on previously granted restricted stock unit and performance share unit awards from December 2023, December 2024, and December 2025 and vest proportionately with those awards. Each right is the economic equivalent of one share of common stock, and no Rule 10b5-1 trading plan is reported.
LEMAITRE VASCULAR INC (LMAT) director John James O'Connor reported five acquisitions of dividend equivalent rights on September 3, 2026. The awards total a small fractional interest in common stock and all are direct derivative holdings tied to previously granted restricted stock unit and performance share unit awards.
According to the footnotes, each dividend equivalent right is the economic equivalent of one share of common stock and accrues on outstanding equity awards, vesting proportionately with those awards. No Rule 10b5-1 trading plan is reported, and no sales or disposals are listed in this filing.
LEMAITRE VASCULAR INC (symbol: LMAT) is the issuer of record for a Form 4 filing submitted to the SEC. LeBlanc Dorian Paul reported acquisition or exercise transactions in this Form 4 filing.
LEMAITRE VASCULAR INC (LMAT) reported that its Chief Financial Officer, Dorian Paul LeBlanc, received small awards of additional Dividend Equivalent Rights on September 3, 2026 tied to prior restricted stock unit (RSU) grants. The awards reflect accrued dividend equivalents and are the economic equivalent of additional shares of common stock.
LEMAITRE VASCULAR INC (LMAT) reported that Chairman and CEO George W. LeMaitre acquired several small blocks of Dividend Equivalent Rights on September 3, 2026. These rights accrued on previously granted restricted stock unit and performance share unit awards from December 2022, December 2023, December 2024, and December 2025 and will vest proportionately with those underlying awards. Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular’s common stock, and no Rule 10b5-1 trading plan is reported in connection with these accruals.